{'fraction_non_alphanumeric': 0.01938610662358643, 'fraction_numerical': 0.014539579967689823, 'mean_word_length': 5.739130434782608, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor MS‐275 in retinoid‐resistant prostate cancer cells

In retinoid resistant epithelial tumors, the lack of retinoic acid receptor β2 (RARβ2) expression due to epigenetic silencing impairs the activation of retinoid target genes including RARβ2, and has been associated with the development of cancer. In this study we developed a strategy to monitor the re‐activation of RARβ2 by chromatin remodeling agents combined with retinoids in real time, and to correlate the RARβ2 re‐activation with anti‐tumor activity.